Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2021-10-13 Director's Dealing
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-10-13 English
FORM 4
Director's Dealing
2021-10-13 English
FORM 4
Director's Dealing
2021-10-13 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Pyxis Oncology, Inc. It includes extensive information typical of a registration statement/prospectus filed under the Securities Act of 1933, specifically a Form 424B4, which is a prospectus supplement. The document contains sections such as Risk Factors, Use of Proceeds, Capitalization, Management's Discussion and Analysis, Business Description, Executive Compensation, Principal Stockholders, and Financial Statements. It is not an annual or quarterly report, earnings release, or any other type of report but rather a capital markets filing related to the issuance of new shares to the public. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through the IPO. The document length (15,000 characters) and content confirm it is the actual prospectus, not just an announcement of a report publication or a short notice. Therefore, the correct classification is CAP with high confidence.
2021-10-08 English
Regulatory Filings 2021
Regulatory Filings
2021-10-08 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the registration of additional shares, references to prior registration statements, and legal consents. This type of filing is related to capital raising activities and financing. It is not an annual or quarterly report, audit report, earnings release, or any other type of report listed. The document is clearly a capital/financing update related to a securities offering registration.
2021-10-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.